small molecules

BridgeBio aces phase 3 rare disease test, clearing path to FDA

BridgeBio has vaulted over the success bar it set for the trial, linking the candidate to significant improvements on biomarker and clinical outcomes.

Nick Paul Taylor Oct 27, 2025 7:00am

An arrow incrementally going up stairs before pointing straight up Blue background

Praxis plots path to FDA after phase 3 wins in essential tremor

Oct 16, 2025 11:48am

Graphic image of an arrow nailing the bullseye of a target

Lilly pads oral GLP-1 case with pair of phase 3 diabetes wins

Oct 15, 2025 9:48am

3D Rendering futuristic robot technology development artificial intelligence

Merck inks $349M biobucks deal to apply AI to tricky targets

Sep 23, 2025 7:00am

Open farm gate leading into agricultural landscape

Lilly links up with Gate in $856M biobucks deal

Jul 24, 2025 2:32pm

Novo Nordisk inks $812M Deep Apple deal to pursue obesity target

Jun 11, 2025 7:00am